Raynauds Disease Treatment Market Report 2026

Raynauds Disease Treatment Market Overview

• Raynauds Disease Treatment market size has reached to $1.49 billion in 2025 • Expected to grow to $2.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Autoimmune Disorders Fueling The Growth Of The Market Due To Increasing Demand For Symptom Management And Complication Prevention • Market Trend: Innovative Oral Calcium Channel Blockers Lead Raynaud’s Disease Treatment Advances • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Raynauds Disease Treatment Market?

Raynauds disease treatment refers to medical and lifestyle strategies aimed at reducing the frequency and severity of blood vessel spasms in the fingers and toes triggered by cold or stress. It includes medications such as calcium channel blockers to improve blood flow and preventive measures such as keeping warm and managing stress. The main types of treatments in raynaud's disease treatment are medication, thermal therapies, surgical procedures, and alternative therapies. Medications include drugs like calcium channel blockers or vasodilators that help improve blood flow and reduce the severity of Raynaud’s symptoms. It includes different drug classes such as calcium channel blockers, vasodilators, and antiplatelet agents, administered through oral, topical, injectable, and intravenous routes. It serves end users such as hospitals, specialty clinics, homecare settings, and pharmacies.

What Is The Raynauds Disease Treatment Market Growth Forecast?

The raynauds disease treatment market size is expected to see strong growth in the next few years. It will grow to $2.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to development of novel pharmacological therapies, adoption of wearable thermal therapy devices, increasing awareness of preventive care and lifestyle management, growth in homecare and telehealth services, integration of digital health monitoring and biofeedback technologies. Major trends in the forecast period include rising adoption of calcium channel blockers and vasodilators, increased use of thermal therapy devices and biofeedback systems, growing preference for minimally invasive surgical procedures, expansion of homecare and specialty clinic settings, emphasis on lifestyle and stress management programs.

Global Raynauds Disease Treatment Market Segmentation

1) By Treatment Type: Medication, Thermal Therapies, Surgical Procedures, Alteative Therapies 2) By Drug Class: Calcium Channel Blockers, Vasodilators, Antiplatelet Agents 3) By Route of Administration: Oral, Topical, Injectable, Intravenous 4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Pharmacies Subsegments: 1) By Medication: Calcium Channel Blockers, Alpha Blockers, Vasodilators, Topical Nitrates, Selective Serotonin Reuptake Inhibitors (SSRIs), Phosphodiesterase Inhibitors, Angiotensin Receptor Blockers (ARBs) 2) By Thermal Therapies: Hand Warmers, Thermal Gloves, Heated Pads, Biofeedback-Controlled Thermal Devices 3) By Surgical Procedures: Sympathectomy, Nerve Decompression Surgery, Vascular Surgery 4) By Alternative Therapies: Acupuncture, Biofeedback Therapy, Herbal Remedies, Nutritional Supplements, Stress Management Techniques

What Are The Drivers Of The Raynauds Disease Treatment Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the raynauds disease treatment market going forward. Autoimmune diseases refer to conditions in which the immune system mistakenly attacks the body's own healthy tissues, causing inflammation and damage. The rise in prevalence of autoimmune diseases is due to people living in more urbanized and sanitized environments, leading to less immune system training, and modern lifestyle factors such as poor diet, stress, and environmental pollutants. Raynaud’s disease treatment helps the autoimmune disease by allowing better management of symptoms, reducing tissue damage, and preventing complications that arise from impaired blood flow. For instance, in February 2024, according to Clinical Trials Arena, a UK-based clinical trials and pharmaceutical developments platform, projected trends indicate that rheumatoid arthritis (RA) cases worldwide are expected to rise sharply, with prevalence anticipated to grow by 80.2% and affect nearly 1% of the global population by 2050. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the raynauds disease treatment industry. The rising healthcare expenditure is expected to propel the growth of the raynauds disease treatment market going forward. Healthcare expenditure refers to the total amount of money spent on medical services, treatments, and health-related resources within a given period. Healthcare expenditure is rising significantly as the aging population grows, leading to a higher demand for medical services, long-term care, and age-related treatments, which collectively place a greater financial burden on healthcare systems. Healthcare expenditure improves Raynaud’s disease treatment by enabling better access to medications, advanced diagnostics, specialized care, research for new therapies, and public awareness programs that help manage symptoms effectively. For instance, in April 2025, according to the American Medical Association, a US-based professional association, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth recorded in 2022. Therefore, the rising healthcare expenditure is driving the growth of the raynauds disease treatment industry.

Key Players In The Global Raynauds Disease Treatment Market

Major companies operating in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, Viatris Inc., Lupin Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd.

Global Raynauds Disease Treatment Market Trends and Insights

Major companies operating in the raynauds disease treatment market are focusing on developing innovative solutions for treating raynauds disease, such as oral calcium channel blockers to improve blood flow by relaxing and widening blood vessels, thereby reducing the frequency and severity of vasospastic attacks. Oral calcium channel blocker refers to a type of medication taken by mouth that helps relax and widen blood vessels by blocking calcium entry into the muscle cells of the heart and blood vessel walls. For instance, in June 2023, Aisa Pharma Inc., a US-based clinical-stage biopharmaceutical company, launched the second part of its Phase 2b RECONNOITER trial to evaluate Profervia (cilnidipine), an oral calcium channel blocker, for treating raynaud’s phenomenon in people with systemic sclerosis (SSc). This follows promising results from the first phase, where Profervia showed a greater reduction in raynaud’s attack frequency and SSc disease severity compared to other calcium channel blockers, while also demonstrating a favorable safety profile and good tolerability. The trial, now moving forward with a 20 mg dose, aims to address the urgent need for effective treatments for Raynaud’s in SSc, a condition that currently lacks approved therapies.

Regional Insights

North America was the largest region in the raynauds disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Raynauds Disease Treatment Market?

The raynauds disease treatment market consists of revenue earned by entities by providing services such as pharmacological management, thermal therapy services, surgical consultation, and behavioral therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The raynauds disease treatment market also includes sales of vasodilators, prostaglandins, hand warmers, thermal gloves, heated socks, and paraffin wax baths. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Raynauds Disease Treatment Market Report 2026?

The raynauds disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the raynauds disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.